| 名稱 | Wnt-C59 |
| 描述 | Wnt-C59 (C59) is a highly effective and specific Wnt signaling antagonis with PORCN enzymatic activity. |
| 細(xì)胞實(shí)驗(yàn) | Wnt-C59 (C59) is dissolved in DMSO (10 mM) and stored, and then diluted with appropriate medium before use[1]. Approximately, 1×104 cells are seeded in 24-well plates, and Wnt-C59 (5 μM, 10 μM, and 20 μM) is added the next day. Each group is tested in triplicate and control groups with addition of DMSO are also established. Cell confluence is determined by microscopy at 24, 48, 72, and 96 hours after seeding of cells. The IC50 of Wnt-C59 is determined by MTT assay, using 96-well dishes. Next day, various concentrations of Wnt-C59 are added, and cellular viabilities are measured by a spectrophotometer at both 24 and 48 hours. For sphere formation, approximately one hundred cells are seeded onto the Low Cell Bind Surface 24-well Nunc dish. Each group is done in triplicate and each well had 2 mL medium. Media are changed twice a week, and only half of the media is changed each time. Approximately, 1×103 cells are seeded for each well in the sphere inhibition assay. At 1 to 5 days after plating, all tested cells formed small spheres. Five days later, Wnt-C59 (1 μM, 5 μM, and 20 μM) is added into experimental groups. Abilities for cell growth and sphere images are compared and recorded at the end of the first, second, and third weeks after addition of Wnt-C59, or DMSO in control groups. The sphere growths are observed and recorded daily under microscopy, and the area of spheres is analyzed using Metamorph and recorded as average area (μm2)[1]. |
| 激酶實(shí)驗(yàn) | Aurora A radioactive Flashplate enzyme assay: Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates. |
| 體外活性 | 在原位移植獨(dú)立性MMTV-WNT1腫瘤的雌性裸鼠中,Wnt-C59（10 mg/kg）能夠降低β-catenin靶向基因的表達(dá),降低Wnt通路活性,抑制腫瘤細(xì)胞生長.14CREER/Rosa-SmoM2小鼠中,Wnt-C59（5 mg/kg）局部給藥能夠抑制細(xì)胞增殖. |
| 體內(nèi)活性 | 在轉(zhuǎn)染PORCN的無PORCN HT1080細(xì)胞中,Wnt-C59（100 nM ）抑制PORCN活性。在轉(zhuǎn)染W(wǎng)NT3A-V5的HeLa細(xì)胞中,Wnt-C59（10 -100 nM）能夠抑制PORCN酰基轉(zhuǎn)移酶活性。 |
| 存儲條件 | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | Ethanol : 7.6 mg/mL (20 mM)
DMSO : 7.6 mg/mL (20 mM)
|
| 關(guān)鍵字 | Wnt | WntC59 | Inhibitor | Porcupine | Wnt-C59 | Wnt-C-59 | inhibit | C 59 | C-59 | Wnt C59 |
| 相關(guān)產(chǎn)品 | Urea | Bisdemethoxycurcumin | PRI-724 | Nefopam hydrochloride | XAV-939 | EMT inhibitor-1 | MSAB | TNIK-IN-3 | (E)-Ferulic acid | CHIR-99021 | Wogonin | Wnt pathway activator 1 |
| 相關(guān)庫 | 抑制劑庫 | 神經(jīng)保護(hù)化合物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 抗結(jié)直腸癌化合物庫 | 成骨分子庫 | 干細(xì)胞分化化合物庫 | 口服活性化合物庫 | 神經(jīng)元分化化合物庫 | Wnt/Hedgehog/Notch 通路化合物庫 |